Want to see CTNM full AI Analyst Report?
Top Page
Contineum Therapeutics, Inc. Class A
(NASDAQ:CTNM)
Select Model
Select Model
Rating:44Neutral
Price Target:
$13.00
▼(-23.62% Downside)
Action:Reiterated
Date:10/01/26
The score is primarily held down by weak financial performance (no revenue, sizable losses, and worsening cash burn) and bearish-to-neutral technicals (below key moving averages with negative MACD). A relatively solid balance sheet and some positive strategic messaging help, but the recent Phase 2 miss and lack of valuation support (negative P/E, no dividend) keep the overall score low.
Positive Factors
Low leverage and solid equity base
The company currently has a comparatively strong balance sheet, with debt small relative to equity and assets. This provides flexibility to continue funding research and operations, absorb development setbacks, and pursue clinical opportunities without the immediate burden of heavy leverage.
Negative Factors
No recurring commercial revenue
The absence of current revenue leaves the company dependent on financing or potential collaboration proceeds while it funds development. Large operating and net losses also indicate that the business has not yet established a self-sustaining commercial model or dependable earnings base.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and solid equity base
The company currently has a comparatively strong balance sheet, with debt small relative to equity and assets. This provides flexibility to continue funding research and operations, absorb development setbacks, and pursue clinical opportunities without the immediate burden of heavy leverage.
Read all positive factors
Contineum Therapeutics, Inc. Class A (CTNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$503.37M
Dividend YieldN/A
Average Volume (3M)620.55K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue GrowthN/A
EPS Growth21.01%
CountryUS
Employees51
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.73
Shares Outstanding32,958,633
10 Day Avg. Volume811,770
30 Day Avg. Volume620,553
Financial Highlights & Ratios
PEG Ratio-0.16
Price to Book (P/B)1.21
Price to Sales (P/S)0.00
P/FCF Ratio-5.70
Enterprise Value/Market Cap0.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.82
Forecast
1Y Price Target
$22.29Price Target Upside30.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.72
Revenue Forecast (FY)$5.00M
Contineum Therapeutics, Inc. Class A Business Overview & Revenue Model
Company Description
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIP...
How the Company Makes Money
As a clinical-stage biotechnology company, Contineum Therapeutics does not typically generate recurring revenue from product sales unless it has approved and commercialized drugs; information confirming any marketed/approved products and related s...
Contineum Therapeutics, Inc. Class A Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 50.00M | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -258.00K | 50.00M | 0.00 | 0.00 |
| EBITDA | -66.00M | -67.74M | -42.00M | 23.57M | -23.54M | -28.34M |
| Net Income | -57.56M | -59.98M | -42.26M | 22.72M | -24.25M | -29.00M |
Balance Sheet | ||||||
| Total Assets | 250.37M | 276.64M | 212.85M | 130.39M | 50.64M | 70.52M |
| Cash, Cash Equivalents and Short-Term Investments | 236.55M | 262.90M | 204.76M | 125.19M | 47.24M | 69.00M |
| Total Debt | 6.57M | 8.25M | 6.26M | 193.19M | 5.85M | 4.91M |
| Total Liabilities | 10.71M | 15.65M | 14.78M | 198.32M | 11.37M | 8.93M |
| Stockholders Equity | 239.66M | 260.99M | 198.07M | -67.94M | 39.27M | 61.59M |
Cash Flow | ||||||
| Free Cash Flow | -53.46M | -55.54M | -33.36M | 18.93M | -20.24M | -26.43M |
| Operating Cash Flow | -53.01M | -55.31M | -32.84M | 19.35M | -20.12M | -26.27M |
| Investing Cash Flow | -66.97M | -3.71M | -69.74M | -65.57M | 22.30M | -64.97M |
| Financing Cash Flow | 113.90M | 112.69M | 109.00M | 56.18M | -1.24M | 79.84M |
Contineum Therapeutics, Inc. Class A Technical Analysis
Negative
17.02
Price Trends
14.74
Negative
14.17
Negative
13.74
Negative
Market Momentum
-0.53
Negative
47.69
Neutral
80.21
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTNM, the sentiment is Negative. The current price of 17.02 is above the 20-day moving average (MA) of 13.10, above the 50-day MA of 14.74, and above the 200-day MA of 13.74, indicating a neutral trend. The MACD of -0.53 indicates Negative momentum. The RSI at 47.69 is Neutral, neither overbought nor oversold. The STOCH value of 80.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTNM.
Contineum Therapeutics, Inc. Class A Risk Analysis
Contineum Therapeutics, Inc. Class A disclosed 78 risk factors in its most recent earnings report. Contineum Therapeutics, Inc. Class A reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Contineum Therapeutics, Inc. Class A Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $1.33B | -13.86 | -138.12% | ― | ― | -115.15% | |
52 Neutral | $115.94M | -6.18 | -2.10% | 3.50% | ― | -9.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $455.23M | -3.20 | -56.60% | ― | -100.00% | -49.28% | |
48 Neutral | $254.91M | -3.79 | -27.15% | ― | ― | 45.56% | |
45 Neutral | $13.74M | -0.37 | -145.40% | ― | -100.00% | 82.57% | |
44 Neutral | $503.37M | -7.73 | -24.73% | ― | ― | 21.01% |
* Healthcare Sector Average
CTNM
Contineum Therapeutics, Inc. Class A
13.38
1.45
12.15%
TVRD
Tvardi Therapeutics
1.03
-5.66
-84.60%
CAPR
Capricor Therapeutics
7.83
1.11
16.52%
DRTS
Alpha Tau
14.41
10.48
266.67%
IMRX
Immuneering
3.94
-2.20
-35.83%
ENGN
enGene Holdings
1.73
-6.56
-79.13%
Contineum Therapeutics, Inc. Class A Corporate Events
Business Operations and StrategyProduct-Related Announcements
Contineum Therapeutics Reports Phase 2 MOONLIGHT-1 Results
Negative
Sep 14, 2026
On September 14, 2026, Contineum Therapeutics reported top-line Phase 2 results from the MOONLIGHT-1 proof-of-concept trial of JNJ-5120/PIPE-307 in adult patients with major depressive disorder. The randomized, double-blind, placebo-controlled stu...
Business Operations and StrategyRegulatory Filings and Compliance
Contineum Therapeutics Updates Strategy, Highlights PIPE-791 Leadership
Positive
Jul 13, 2026
On July 13, 2026, Contineum Therapeutics updated its corporate presentation to highlight strategic and business developments, notably emphasizing PIPE-791 as its lead, brain-penetrant LPAR1 antagonist for idiopathic pulmonary fibrosis and chronic ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.